A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

This study is designed to find out how effective and safe a new drug, GSK3862995B, is for adult participants with bronchiectasis, a chronic lung disease. The study will also test how the body processes the drug and to check for any immune reactions. Participants will be divided into groups randomly to receive either one of two different doses of the study drug or a placebo. The main goal of the study is to see how well the drug works compared to the placebo in helping those with bronchiectasis.

NCT Number	NCT07201051
Lead Sponsor	GlaxoSmithKline
Conditions	Bronchiectasis
Enrollment	363 participants
Start Date	2025-10-30
Primary Completion	2027-05-04 (estimated)
Study Completion	2027-12-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-12